Antibody Category
Suppliers
Applications
Antibody Types
Host Species
Species Reactivity
  • Category A

    • Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
    • Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
    • Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
    Search
  • Category B

    • Original source/host: Animal (historic hybridoma) OR naïve, non-immunised animal B cell-derived in vitro antibody display library
    • Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
    • Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
    • Recombinantly reformatted hybridomas are included as they align with the May 2020 EURL ECVAM recommendation, which permits continued use of existing, sequenced, and well-characterised hybridomas to produce recombinant monoclonal antibodies in vitro, as animals are no longer directly involved
    • Naïve, non-immunised animal B cell-derived in vitro antibody display libraries align with the May 2020 EURL ECVAM recommendation to no longer authorise the development and production of antibodies through animal immunisation
    Search
  • Category C

    • Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
    • Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
    • Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation
    Search
  • Category D

    • Original source/host: Animal OR naïve, non-immunised animal B cell-derived in vitro antibody display library
    • Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
    • Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation
    Search
  • Category E

    • Original source/host: Animal
    • Discovery method: immunisation-based selection post 2020
    • Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
    Search
  • Category F

    • Original source/host: Animal
    • Discovery method: immunisation-based selection post 2020
    • Production: Recombinant expression with animal-derived biomaterials used in production or final formulation
    Search
  • Category G

    • Original source/host: Unknown
    • Discovery method: Unknown
    • Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
    Search

Recombinant Anti-HLA-A2-peptide (LLLTVLTVV) Complex (M3B8)


Proteo Genix logo
View Antibody details

Recombinant Anti-HLA-A2-peptide (SLLMWITQV) Complex (3M4E5)


Proteo Genix logo
View Antibody details

Recombinant Anti-HLA-A2-peptide (SLLMWITQV) Complex (3M4F4)


Proteo Genix logo
View Antibody details

Recombinant Anti-HLA-A2-peptide (TDQVPFSV) Complex (1C8)


Proteo Genix logo
View Antibody details

Recombinant Anti-HLA-A2-peptide (YLEPGPVT) Complex (2B2)


Proteo Genix logo
View Antibody details

Recombinant Anti-HLA-A2-peptide (YLEPGPVT) Complex (2C5)


Proteo Genix logo
View Antibody details

Recombinant Anti-HLA-A2-peptide (YLEPGPVT) Complex (2D1)


Proteo Genix logo
View Antibody details

Recombinant Anti-HLA-A2-peptide (YLEPGPVT) Complex (2F1)


Proteo Genix logo
View Antibody details

Refanezumab Biosimilar – Anti-MAG/ SIGLEC-4A mAb – Research Grade


Proteo Genix logo
View Antibody details

Reflocibart Biosimilar – Anti-VRF mAb – Research Grade


Proteo Genix logo
View Antibody details